# UNCY — Unicycive Therapeutics Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** UNCY  
**Sources:** 21  
**Published:** 2026-11-01  
**Canonical:** https://app.k3vl4r.com/research/deep-research-uncy-unicycive-therapeutics-inc-catalysts-narrative-risk-10526

---

## Overview

Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is a clinical-stage biotechnology company based in Mountain View, CA, focused on kidney diseases [[3]](https://www.rttnews.com/companies/44972/unicycive-therapeutics-inc-uncy), [[19]](https://ir.unicycive.com/). Its lead candidate, oxylanthanum carbonate (OLC), is an investigational oral phosphate binder being developed for hyperphosphatemia in patients with chronic kidney disease on dialysis [[3]](https://www.rttnews.com/companies/44972/unicycive-therapeutics-inc-uncy), [[19]](https://ir.unicycive.com/). A second candidate, UNI-494, targets acute kidney injury [[19]](https://ir.unicycive.com/). As of late October 2026 the company's market capitalization was roughly $104M–$134M depending on the date and price snapshot [[1]](https://catalystalert.io/research/UNCY), [[16]](https://www.ad-hoc-news.de/boerse/news/nebenwerte/unicycive-therapeutics-stock-holds-at-usd-4-80/70138154), [background], placing it in the small-cap, single-catalyst biotech category. All figures should be treated as point-in-time and verified before use [[1]](https://catalystalert.io/research/UNCY).

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-uncy-unicycive-therapeutics-inc-catalysts-narrative-risk-10526 (free to sign up)._